Late results of a randomized trial on the role of mild hypofractionated radiotherapy for the treatment of localized prostate cancer

Conclusion: No difference in the toxicity profile could be identified between hypofractionation and conventional fractionation. Our schedule of 2,25Gy/fr seems safe and tolerable by the patients with acceptable rates of acute and late toxicity.

Source: Journal of Cancer - July 2, 2020 Category: Cancer & Oncology Authors: Petros Alexidis, Sotirios Karatzoglou, Dimitris Dragoumis, Konstantinos Drevelegas, Ioannis Tzitzikas, Konstantinos Hatzimouratidis, Ioannis Chrisogonidis, Aris Ioannidis, Iason Nikolaos Katsios, Paul Zarogoulidis, Konstantinos Sapalidis, Charilaos Koulou Tags: Research Paper Source Type: research